Gentian Diagnostics AS (GENT) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Gentian Diagnostics AS stock NOK 43.01, price NOK 39.10, upside +10.0%, quality 68 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range kr 34.60 – kr 84.16 · fair‑value band kr 32.47 – kr 53.53 · the kr 39.10 price screens below the kr 43.01 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Gentian Diagnostics AS in your weekly email
Every Wednesday you see whether Gentian Diagnostics AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe.
Show moreShow less
It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum.
The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency.
Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.
Stock analysis
Gentian Diagnostics AS (GENT) currently trades at kr 39.10, while our model-based Fair Value estimate is kr 43.01, so the stock looks roughly fairly valued today (gap 9.1%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of kr 50.49 per share, and 12 of the 26 models we run sit above the kr 39.10 price.
Bear case: the Dividend Discount group reads lowest at kr 5.34, and 14 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: kr 32.47 (bear) to kr 53.53 (bull), the price of kr 39.10 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Gentian Diagnostics AS reported revenue of 176M NOK in FY2025 versus 83.1M NOK in FY2021, a compound +20.7%/yr. Reported net income was 13.3M NOK in FY2025.
Key figures
Market cap 603M NOK (≈ $63.9M) Micro · P/S ratio 3.22 · EPS (TTM) kr −0.3300 · Dividend yield 1.5% · Net margin −2.6% · Return on equity −2.6% · Return on assets (EBIT) −2.7% (5-year average) · Operating margin 22.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 10%, GENT screens cheaper than that median.
Fair Value models
Bearkr 32.47Fair Value kr 43.01Bullkr 53.53
Price kr 39.10 · Upside +10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+16.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.9%
Start year 2020 (pandemic). Over 10 years: +21.3% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−26.1% (2020) → 14.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Norway: IMF forecast 2.4% a year to 2030, 3.3% from 2016 to 2025) that is about +6.3% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside+10.0% · Top 25%
Profitability
Return on assets5.1% · Above median
Net margin (12 months)−2.6% · Below median
Operating margin (12 months)22.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)22.1% · Top 25%
Dividend yield (12 months)1.5% · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B2.94× · Pricier than median
P/S (12 months)3.15× · Pricier than median
Price / free cash flow (fiscal year)18.9× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Gentian Diagnostics AS Fair Value". https://www.fairvalue-calculator.com/stock/GENT
Frequently asked questions
Is Gentian Diagnostics AS (GENT) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of kr 43.01 versus a price of kr 39.10, about +10% upside (fairly valued).
What is the fair value of GENT?
Our model-based fair value for Gentian Diagnostics AS is kr 43.01 (as of Nov 8, 2026), built from audited fundamentals. The current price: kr 39.10.
What is the quality score of GENT?
Gentian Diagnostics AS has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gentian Diagnostics AS (GENT)?
Our model-based price target is the fair value of kr 43.01 (as of Nov 8, 2026) from 26 valuation models. Cautious scenario kr 32.47, optimistic scenario kr 53.53. It is a calculation from audited fundamentals, not an analyst target.
What is the Gentian Diagnostics AS stock forecast for 2026?
Our models put fair value at kr 43.01, about +10% upside versus a price of kr 39.10 (fairly valued). Cautious scenario kr 32.47, optimistic scenario kr 53.53. The calculation is refreshed regularly with new filings.
What is the revenue of Gentian Diagnostics AS (GENT)?
Gentian Diagnostics AS reported trailing-twelve-month revenue of about 191M NOK (latest available figure, as of Nov 8, 2026).
Does Gentian Diagnostics AS pay a dividend?
Gentian Diagnostics AS currently shows a dividend yield of 1.53% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Gentian Diagnostics AS (GENT) and when is the ex-dividend date?
Gentian Diagnostics AS pays a dividend of kr 0.6 per share a year, a dividend yield of 1.5%. The last ex-dividend date was May 6, 2026. The payout ratio is 70.0% of earnings. Free cash flow covers the dividend 3.43 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Gentian Diagnostics AS (GENT)?
For today's price to be fair in a discounted-cash-flow model, Gentian Diagnostics AS would have to grow free cash flow by +8.8 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +20.9 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of GENT use?
Our models discount Gentian Diagnostics AS at 11.0 %: a base by market capitalisation (micro), damped by beta 0.52, country premium for Norway. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Gentian Diagnostics AS that is +8.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has Gentian Diagnostics AS (GENT) delivered so far?
Over the past 5 years revenue at Gentian Diagnostics AS grew +20.9 % a year. The price currently implies free-cash-flow growth of +8.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Gentian Diagnostics AS (GENT) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Gentian Diagnostics AS (+8.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Gentian Diagnostics AS (GENT)?
The free-cash-flow yield on the price is 5.28 %: that much free cash flow Gentian Diagnostics AS produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Gentian Diagnostics AS (GENT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gentian Diagnostics AS it is kr 43.01 per share (as of Nov 8, 2026), against a price of kr 39.10. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Gentian Diagnostics AS stock overvalued or undervalued in 2026?
As of Nov 8, 2026, GENT trades below its calculated fair value: price kr 39.10, fair value kr 43.01, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GENT?
No. The price is what the market pays today (kr 39.10); the fair value is what the company's own numbers justify (kr 43.01). For Gentian Diagnostics AS the two are kr 3.91 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gentian Diagnostics AS worth?
The market values Gentian Diagnostics AS at about 603M NOK (market capitalisation, as of Nov 8, 2026). Per share that is kr 39.10; our models calculate a fair value of kr 43.01 per share.
What do the bullish and bearish scenarios say about GENT?
Our models span a range for Gentian Diagnostics AS: cautious scenario kr 32.47, base kr 43.01, optimistic kr 53.53 per share (as of Nov 8, 2026, price kr 39.10). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Gentian Diagnostics AS (GENT)?
Balance-sheet figures for Gentian Diagnostics AS (as of Nov 8, 2026): return on equity −2.6%. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is GENT from its 52-week high?
Gentian Diagnostics AS trades at kr 39.10, about 33% below its 52-week high of kr 58.21 and 13% above the low of kr 34.60 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 43.01 is for.
Which stocks are comparable to Gentian Diagnostics AS?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gentian Diagnostics AS stock attractive at the current price?
The data as of Nov 8, 2026: price kr 39.10, calculated fair value kr 43.01 (+10%), Quality Score 68/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GENT calculated?
We run Gentian Diagnostics AS through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of kr 43.01 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Gentian Diagnostics AS currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gentian Diagnostics AS (GENT)?
The closing price on Nov 6, 2026 was kr 39.10. Our model-based fair value is kr 43.01, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gentian Diagnostics AS right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Gentian Diagnostics AS
How large is the market capitalisation of Gentian Diagnostics AS (GENT)?
The market capitalisation of Gentian Diagnostics AS is 603M NOK (≈ $63.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gentian Diagnostics AS (GENT)?
The price-to-sales ratio of Gentian Diagnostics AS is 3.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Gentian Diagnostics AS (GENT)?
Earnings per share at Gentian Diagnostics AS are kr −0.3300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Gentian Diagnostics AS (GENT)?
The dividend yield of Gentian Diagnostics AS is 1.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Gentian Diagnostics AS (GENT)?
The net margin of Gentian Diagnostics AS is −2.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gentian Diagnostics AS (GENT)?
The return on equity (ROE) of Gentian Diagnostics AS is −2.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gentian Diagnostics AS (GENT)?
On an EBIT basis the return on assets of Gentian Diagnostics AS is −2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gentian Diagnostics AS (GENT)?
The operating margin of Gentian Diagnostics AS is 22.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gentian Diagnostics AS (GENT)?
Revenue at Gentian Diagnostics AS is growing +22.1% versus a year earlier (3y avg +20.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Gentian Diagnostics AS (GENT)?
Earnings per share at Gentian Diagnostics AS are growing +83.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Gentian Diagnostics AS (GENT) hold?
Gentian Diagnostics AS holds more cash than debt, 74.7M NOK net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Gentian Diagnostics AS in the live analysis
One click puts Gentian Diagnostics AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026